Newsletter Vol. 1, No. 3 References

MAKING THE CONNECTION:
THE PROSTATE FACTOR AND ERECTILE DYSFUNCTION

Culley C. Carson III, MD

For Feature Article:

1. Silverman WM. “Alphabet soup” and the prostate: LUTS, BPH, BPE, and BOO. J Am Osteopath Assoc. 2004;104(suppl):S1-S4.
   
   
2. Lepor H. Evaluating men with benign prostatic hyperplasia. Rev Urol. 2004;6(suppl):S8-S15.
   
   
3. Hellstrom WJG. Benign prostatic hyperplasia, sexual function, and overall evaluation of the male patient. J Am Osteopath Assoc. 2004;104(suppl):S5-S10.
   
   
4. Pelman RS. Overview of overactive bladder, prostatitis, and lower urinary tract symptoms for the primary care physician. Rev Urol. 2004;6(suppl):S16-S23.
   
   
5. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol. 2003;44:637-649.
   
   
6. Giovannucci E, Rimm EB, Chute CG, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol. 1994;140:989-1002.
   
   
7. Joseph MA, Harlow SD, Wei JT, et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol. 2003;157:906-914.
   
   
8. Rohrmann S, Smit E, Giovannucci E, Platz EA. Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2004;159:390-397.
   
   
9. Roberts RO, Jacobsen SJ, Rhodes T, et al. Cigarette smoking and prostatism: a biphasic association? Urology. 1994;43:797-801.
   
   
10. Bartsch G, Rittmaster R, Klocker H. Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia. World J Urol. 2002;19:413-425.
    
    
11. Clifford GM, Farmer RD. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol. 2000;38:2-19.
    
    
12. Ekman P. Finasteride in the treatment of benign prostatic hypertrophy. An update: new indications for finasteride therapy. Scand J Urol Nephrol. 1999;33(suppl):15-20.
    
    
13. Kaplan SA. Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual function. Urology. 2004;63:428-434.
    
    
14. Cardura^® (doxazosin) prescribing information. Roerig, Division of Pfizer Inc: New York, NY; 2002.
    
    
15. Flomax^® (tamsulosin) prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc.: Ridgefield, Conn; 2005.
    
    
16. Naderi N, Mochter CA, de la Rosette JJMCH. Real life practice in the management of benign prostatic hyperplasia. Curr Opin Urol. 2004;14:41-44.
    
    
17. Cialis^® (tadalafil) prescribing information. Lilly ICOS LLC: Indianapolis, Ind and Bothell, Wash; 2005.
    
    
18. Levitra^® (vardenafil) prescribing information. Bayer Pharmaceuticals Corp: West Haven, Conn; 2005.
    
    
19. Viagra^® (sildenafil) prescribing information. Pfizer Inc: New York, NY; 2005.
    
    
20. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002;90:836-839.

For Dr. Miner’s Interview:

1. Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms: results of an international study. Eur Urol. 1997;31:272-280.
   
   
2. Rosen RC, Catania J, Pollack L, Althof S, O’Leary M, Seftel AD. Male sexual health questionnaire (MSHQ): scale development and psychometric validation. Urology. 2004;64:777-782.
   
   
3. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey.’ Int J Impot Res. 2000;12:305-311.
   
   
4. Melman A, Gingell JC. The epidemiology and pathophysiology of erectile dysfunction. J Urol. 1999;161:5-11.
   
   
5. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol. 2003;44:637-649.
   
   
6. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003): diagnosis and treatment recommendations. J Urol. 2003;170:530-547.
   
   
7. Garraway WM, Russell EB, Lee RJ, et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract. 1993;43:318-321.
   
   
8. Roberts RO, Rhodes T, Panser LA, et al. Natural history of prostatism: worry and embarrassment from urinary symptoms and health care-seeking behavior. Urology. 1994;43:621-628.
   
   
9. Barry MJ, Fowler FJ Jr, O’Leary MP, et al, for the Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148:1549-1557.
   
   
10. Speakman MJ, Kirby RS, Joyce A, Abrams P, Pocock R, for the British Association of Urological Surgeons. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int. 2004;93:985-990.
    
    
11. Choong S, Emberton M. Acute urinary retention. BJU Int. 2000;85:186-201.
    
    
12. McConnell JD, Roehrborn CG, Bautista OM, et al, for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387-2398.

For Clinical Corner:

1. Hytrin^® (terazosin) prescribing information. Abbott Laboratories: Abbott Park, Ill; 2001.
   
   
2. Kirby RS, Andersen M, Gratzke P, Dahlstrand C, Hoye K. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int. 2001;87:192-200.
   
   
3. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol. 2003;170:530-547.
   
   
4. Flomax^® (tamsulosin) prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc.: Ridgefield, Conn; 2005.
   
   
5. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G, for the ARIA 3001 ARIA 3002 ARIA 3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434-441.